Question 1

What are Gag and Gag-Pol polyproteins in HIV?

Accepted Answer

Gag and Gag-Pol are long precursor protein chains synthesized during HIV replication. Gag supplies the structural components of the virus, while Gag-Pol contains essential viral enzymes including reverse transcriptase, integrase, and protease. These polyproteins move to the host cell membrane where they assemble into immature viral particles.

Question 2

How does viral protease enable HIV maturation?

Accepted Answer

The viral protease, an aspartyl protease encoded within Gag-Pol, catalyzes ordered cleavage of polyproteins into individual structural proteins like matrix, capsid, and nucleocapsid. This proteolytic processing allows viral enzymes to adopt active conformations and triggers reorganization of the virion's internal structure, resulting in the condensed core typical of mature, infectious HIV particles.

Question 3

What is the mechanism of protease inhibitors?

Accepted Answer

Protease inhibitors are antiretroviral drugs that bind to the active site of viral protease, preventing cleavage of viral polyproteins. This blocks the maturation process, leaving virions with improperly processed proteins and disordered internal architecture. While particles still bud from host cells, they remain noninfectious and cannot initiate productive infection.

Question 4

Why are immature HIV virions noninfectious?

Accepted Answer

Immature virions lack properly processed proteins and have disorganized internal structure because polyprotein cleavage has not occurred. Full infectivity requires viral maturation, which depends on the ordered cleavage of Gag and Gag-Pol polyproteins by viral protease. Without this reorganization, virions cannot establish productive infection in new host cells.

Question 5

How do protease inhibitors reduce HIV spread?

Accepted Answer

By blocking viral protease activity, protease inhibitors prevent polyprotein cleavage and virion maturation. This produces structurally immature, noninfectious particles that cannot initiate new infections. Reducing the number of infectious virions slows viral replication and limits HIV spread throughout the body, making protease inhibitors essential components of combination antiretroviral therapy.

Question 6

What happens when protease becomes active during HIV assembly?

Accepted Answer

When several Gag-Pol molecules come together at the host cell membrane, the protease regions form a dimer and become catalytically active. As the viral particle buds from the host cell, the active protease first cleaves itself from the Gag-Pol polyprotein, then cleaves remaining polyproteins into smaller, functional proteins that reorganize virion structure.

Question 7

How does protease inhibitor therapy compare to other antiviral approaches?

Accepted Answer

Protease inhibitors target viral maturation by blocking polyprotein cleavage, distinct from inhibitors of viral protein synthesis that prevent enzyme production. While inhibitors of viral protein synthesis reduce the amount of viral components available, protease inhibitors allow normal synthesis but prevent functional assembly. Both strategies limit HIV replication but through different mechanisms in the viral lifecycle.

Ингибиторы созревания и сборки вирионов

Browse More Videos